ImageneBio (IMA) Stock Price

ImageneBio Price

NASDAQ·CLOSED
4.20
​
Market closed

Revenue at ImageneBio has contracted by 3.0% per year over the past 7 years to 800,000.00 USD. For ImageneBio, the net margin of -5,668.6% is down versus -110.1% a few years ago. The consensus 12-month price target for ImageneBio is 1.33 USD, about 68.3% below where the stock trades today. Of 8 analysts, 6 rate the stock a buy — an overall Buy consensus.

ImageneBio stock price

Access this data via the Eulerpool API

ImageneBio business model & stock analysis

Ikena Oncology Inc is a US-based company operating in industry. The company is headquartered in Boston, Massachusetts and currently employs 33 full-time employees. The company went IPO on 2021-03-26. Ikena Oncology, Inc. is a targeted oncology company. The firm is focused on developing cancer therapies targeting signaling pathways that drive the formation and spread of cancer. Its lead targeted oncology product candidate, IK-930, is an oral small molecule inhibitor of the transcriptional enhanced associate domain (TEAD), transcription factor in the Hippo signaling pathway. The company intends to pursue clinical development of IK-930 across a range of tumor types with known Hippo pathway mutations. Its oncology programs also include extracellular signal-related kinase 5 (ERK5) inhibitor / RAS Signaling Pathway inhibitor program, RAS Pathway discovery programs, Tumor Microenvironment Programs, IK-175, IK-412 and IK-007. The firm is developing a small molecule inhibitor program against ERK5 in the RAS signaling pathway. The company also has early stage discovery programs in targeted oncology in the RAS pathway.

Frequently asked questions about ImageneBio

Analysts currently set an average price target of 1.33 USD for the ImageneBio stock (median: 1.33 USD), implying -68.3 % versus the latest price. The consensus is based on 8 analyst ratings.

8 analysts currently rate the ImageneBio stock: 6 recommend buying, 1 holding and 1 selling. For 2026, analysts expect ImageneBio to generate revenue of 340,244.00 USD and earnings per share of -3.22 USD.

Converted at the current exchange rate, the ImageneBio share trades at 3.75 EUR (4.20 USD).

The ImageneBio share (IMA) is listed on 1 stock exchanges, including: NASDAQ (IKNA).

The expected revenue of ImageneBio is 340,244.00 USD. This figure is based on current financial data and reflects the company's business performance.

The expected profit of ImageneBio is -36.00 M USD. The net profit reflects the company's profitability after deducting all expenses.

The price-to-earnings ratio (P/E) of ImageneBio is currently -1.30. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the ImageneBio stock.

The price-to-sales ratio (P/S) of ImageneBio is currently 138.03. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the ImageneBio stock.

The Eulerpool Quality Score for ImageneBio is 2/10.

The ISIN of ImageneBio is US45175G2075. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The ticker of ImageneBio is IMA. The ticker symbol is used to trade ImageneBio shares on the stock exchange.

Fair ValueTerminal
4.07 USD
Over-/UndervaluationTerminal
Fairly valued
Sector
—
Industry
Other
Number of shares
Employees
Revenue per Employee
53,333.33 USD
Revenue growth Ø5 years
EBIT growth Ø5 years
Net Income growth Ø5 years
Currency
USD
Initial public offering
Mar 26, 2021
ISIN
US45175G2075
Cusip
45175G108
Sedol
BNTB3M7
Market capitalization
46.96 M USDMicro Cap
52-Week Range
PEG
-0.31
P/E ratio
P/Ee 2026
-1.30
P/Ee 2027
-1.21
P/Ee 2028
-1.12
P/Ee 2029
-1.27
P/Ee 2030
-1.11
P/Se
138.03
EV/EBIT
—
P/B Ratio
0.35
ROE (Return on Equity)
ROA (Return on Assets)
ROCE (Return on Capital Employed)
ROIC (Return on Invested Capital)
-31.68 %
Last updated Oct 11, 2026, 5:50 AM

ImageneBio Peer Group

ImageneBio Ticker

NASDAQ · IKNA

All fundamentals and in-depth analysis of ImageneBio

Our stock analysis for ImageneBio stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of ImageneBio. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.